Navigation Links
Gardasil Effective in Preventing Vaginal, Vulvar Cancers, Study Finds

Merck's human papillomavirus vaccine Gardasil is effective in preventing vaginal and vulvar tumors, according to a study to be published on Saturday in the journal Lancet, Dow Jones reports.

Gardasil in clinical trials has been shown to be 100% effective in preventing infection with strains 16 and 18, which together cause about 70% of cervical cancer cases, and about 99% effective in preventing HPV strains 6 and 11, which together with HPV strains 16 and 18 cause about 90% of genital wart cases, among women not already infected with these strains.

FDA in June 2006 approved Gardasil for sale and marketing to girls and women ages nine to 26, and CDC's Advisory Committee on Immunization Practices later that month voted unanimously to recommend that girls ages 11 and 12 receive the vaccine, which is given in a three-shot series. Merck last month announced that it has submitted an application to FDA for extended approval of Gardasil to help prevent vaginal and vulvar cancers.

After three years of follow-up, the study found that the vaccine was 71% effective in preventing vaginal and vulvar cancers related to HPV strains 16 and 18 among women who previously had been exposed to HPV strains 6, 11, 16 and 18.

It was 100% effective among women who previously had not been exposed to those strains. The vaccine was not effective in fighting vaginal or vulvar lesions that had already formed, according to the study.

According to Merck, vaginal and vulvar cancers account for about 3% and 4% of gynecological cancers, respectively. According to HealthDay News/Forbes, HPV is present in about 80% of the 6,000 vaginal and vulvar cancers diagnosed annually in the U.S.


'"/>




Page: 1

Related medicine news :

1. Gardasil vaccine for cervical cancer
2. Gardasil- Cervical Cancer Vaccine Now Approved
3. Gardasil, a cervical cancer vaccine, hits the market
4. Gardasil Hailed as one of the Biggest Research Successes
5. Cervical Cancer Vaccine Gardasil Included In Subsidized CDC program
6. Gardasil Refused Subsidy
7. School Vaccination Program to Include Cancer Drug Gardasil
8. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
9. Gardasil – Cervical Cancer Vaccine in UA
10. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
11. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/21/2017)... , ... September 21, 2017 , ... ... their communities, nine governmental public health departments have been awarded five-year accreditation status ... mean that the benefits of being served by a PHAB-accredited health department ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... The New ... with autism, announced today the election of Yie-Hsin Hung to the Board of Directors. ... join our Board of Directors. Ms. Hung is an invaluable addition to our team,” ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand that specializes ... to the athletic wear market with the launch of their FlipBelt Crops. , The ... essentials securely at their fingertips while at the gym, on the trail, or on-the-go. ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... Prescott, Arizona, is now accredited by The Joint Commission for chemical dependency and ... accredits and certifies U.S. health care organizations that meet the commission’s rigorous standards. ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... voice for people who have kidney disease. The theme “Describe a positive decision ... stories. Entrants needed to meet only one qualification— to have been diagnosed ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... FRANCISCO , Sept. 12, 2017  ValGenesis ... Management Solutions (VLMS), is pleased to announce the ... a member of its Board of Directors and ... ValGenesis VLMS enables life science companies to manage ... the use of paper in this process. Furthermore, ...
(Date:9/9/2017)... , Sept. 9, 2017  Eli Lilly and Company ... and secondary endpoint data for lasmiditan, an investigational, oral, ... demonstrated statistically significant improvements compared to placebo in the ... today at the 18th Congress of the International Headache ... "The data presented today demonstrate lasmiditan,s potential to ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
Breaking Medicine Technology: